FDA approves first anti-diarrheal drug for HIV/AIDS patients — Fulyzaq is the second botanical drug approved by the agency – The U.S. Food and Drug Administration approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
For those short on time, aerobic, not resistance, exercise is best bet for weight, fat loss – When it comes to weight loss and fat loss, aerobic training is better than resistance training. A new study entitled “Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults” has revealed this.
Hillary Clinton in New York Hospital for treatment for blood clot from the concussion – Secretary of State Hillary Clinton was hospitalized Sunday after doctors discovered a blood clot during a follow-up exam related to a concussion she suffered this month.
Mount Sinai survey shows that nearly 1 in 3 children with food allergies experience bullying – Nearly a third of children diagnosed with food allergies who participated in a recent study are bullied. Almost eight percent of children in the U.S. are allergic to foods such as peanuts, tree-nuts, milk, eggs, and shellfish.
People with Asperger’s rarely harm others, so don’t be so quick to link Adam Lanza’s actions with syndrome – Adam Lanza, the 20-year-old gunman in the Sandy Hook school shooting is thought to have had Asperger’s syndrome, a mild form of autism characterized by social awkwardness, but not violence.
Majority of the world living longer, but spending more years in poor health compared to 20 years ago – Comparing healthy life expectancy for 187 countries, in 1990 and 2010, the researchers were able to evaluate major patterns and trends in global health over two decades. They found that life expectancy has increased in 19 of 21 regions around the world, but, although people are living longer, they are spending these later years living with poor health.
Talking therapy cuts depression — Cognitive behavioral therapy may help when antidepressants don’t – Depression is predicted to become the leading cause of disability in high income countries by 2030, and currently only a third of patients with depression respond fully to antidepressant medication.
Social media may be an effective way to help children overcome obesity — Parental involvement and online interaction with counselors and peers led to greater success for overweight and obese children and teens in some studies – Social media like Facebook may be an effective tool to help children overcome obesity, according to a new American Heart Association scientific statement published in the journal Circulation.
Steps taken to meet increasing demand for doctors in India – Various steps have been taken to liberalise norms for opening new medical colleges, besides amending relevant MCI regulations to meet the increasing demand for doctors in India.
Prenatal intervention reduces learning deficit in mice — NIH study shows improvements in animals with Down syndrome characteristics – Mice with a condition that serves as a laboratory model for Down syndrome perform better on memory and learning tasks as adults if they were treated before birth with neuroprotective peptides, according to researchers at the National Institutes of Health.
Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro — Acquisition Expands Baxter’s Role as Global Provider of Dialysis Products – Baxter International Inc. (NYSE:BAX) has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK (approximately $4.0 billion USD at current exchange rates).
Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer’s Disease – Although several pharmaceutical companies in US have experienced setbacks with Alzheimer’s compounds, Merck & Co., Inc. hopes to defy the odds with plans to take a Alzheimer pill into a Phase II/III clinical study with patients who suffer from mild-to-moderate stages of the Alzheimer’s disease.
